Italian Registry of Arthritis on Biologic Therapy

Launched by GRUPPO ITALIANO STUDIO EARLY ARTHRITIS · Mar 2, 2012

Keywords

ClinConnect Summary

The Italian Registry of Arthritis on Biologic Therapy is a clinical trial focused on understanding how effective and safe biologic drugs are for patients with rheumatoid arthritis and related conditions, like ankylosing spondylitis and psoriatic arthritis. These drugs target specific parts of the immune system to help individuals whose arthritis hasn’t improved with standard treatments. Since these biologic therapies have only been available for a few years, researchers are collecting long-term data to see how well they work and if there are any safety concerns over time.

To be eligible for this trial, participants should have a confirmed diagnosis of rheumatoid arthritis, ankylosing spondylitis, or psoriatic arthritis, and their condition should still be active despite trying traditional medications. The trial is open to all adults aged 18 and older who qualify for the new biologic treatments. If you choose to participate, you will be part of a long-term study that tracks your health and treatment outcomes, helping doctors understand better how these new therapies can help people with these challenging conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Clinical diagnosis of Rheumatoid arthritis, Ankylosing spondylitis, Psoriatic arthritis
• • Patients with active disease refractory to traditional disease modifying drugs (methotrexate, leflunomide, sulphasalazine, cyclosporine, hydrossiclorochine)
• • Patients eligible to begin conventional biologic therapy
• Exclusion Criteria:
• • Any criteria excluding treatment with biologic drugs according to international guidelines